The 96th edition of the HPRA Drug Safety Newsletter includes information on the following medicines:

• 'Ulipristal acetate 5mg (Esmya) for uterine fibroids – suspension of marketing authorisation during ongoing review of liver injury risk
• Paracetamol – reminder to prescribers on risk of hepatotoxicity in patients with risk factors
• Durvalumab (Imfinzi^▼) – risk of myasthenia gravis
• Rivaroxaban (Xarelto) – not for use as thromboprophylaxis in patients who have recently undergone transcatheter aortic valve replacement
• Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-norepinephrine reuptake inhibitors (SNRI) – persistent sexual dysfunction after drug withdrawal'.

For further newsletters, including the 97th edition which published today please visit the HPRA website.